-DOCSTART- -X- O
OBJECTIVE -X- _ O
: -X- _ O
Spontaneous -X- _ B-Patient
intracerebral -X- _ I-Patient
hemorrhage -X- _ I-Patient
( -X- _ I-Patient
ICH -X- _ I-Patient
) -X- _ I-Patient
is -X- _ O
caused -X- _ O
by -X- _ O
the -X- _ O
rupture -X- _ O
of -X- _ O
small -X- _ O
blood -X- _ O
vessels -X- _ O
and -X- _ O
other -X- _ O
health -X- _ O
problems. -X- _ O
In -X- _ O
ICH -X- _ O
patients -X- _ O
, -X- _ O
hematoma -X- _ O
enlargement -X- _ O
is -X- _ O
the -X- _ O
most -X- _ O
critical -X- _ O
risk -X- _ O
factor -X- _ O
for -X- _ O
poor -X- _ O
outcomes. -X- _ O
Tranexamic -X- _ B-Intervention
acid -X- _ I-Intervention
, -X- _ O
an -X- _ O
anti-fibrinolytic -X- _ O
agent -X- _ O
, -X- _ O
has -X- _ O
been -X- _ O
used -X- _ O
to -X- _ O
reduce -X- _ O
hematoma -X- _ B-Outcome
expansion. -X- _ I-Outcome
We -X- _ O
analyzed -X- _ O
the -X- _ O
risk -X- _ O
factors -X- _ O
for -X- _ O
hematoma -X- _ B-Comparison
expansion -X- _ I-Comparison
in -X- _ I-Comparison
ICH -X- _ I-Comparison
patients -X- _ I-Comparison
and -X- _ I-Comparison
compared -X- _ I-Comparison
the -X- _ I-Comparison
predictability -X- _ I-Comparison
of -X- _ I-Comparison
hematoma -X- _ I-Comparison
expansion -X- _ I-Comparison
in -X- _ I-Comparison
ICH -X- _ I-Comparison
patients -X- _ I-Comparison
with -X- _ I-Comparison
the -X- _ I-Comparison
use -X- _ I-Comparison
of -X- _ I-Comparison
tranexamic -X- _ I-Comparison
acid. -X- _ I-Comparison
METHODS -X- _ O
: -X- _ O
We -X- _ O
performed -X- _ O
retrospective -X- _ O
analysis -X- _ O
of -X- _ O
ICH -X- _ O
patients -X- _ O
who -X- _ O
underwent -X- _ O
follow-up -X- _ O
computed -X- _ O
tomography -X- _ O
scans -X- _ O
from -X- _ O
October -X- _ O
2008 -X- _ O
to -X- _ O
October -X- _ O
2018. -X- _ O
Of -X- _ O
the -X- _ O
329 -X- _ O
included -X- _ O
patients -X- _ O
, -X- _ O
67 -X- _ O
who -X- _ O
received -X- _ O
tranexamic -X- _ B-Intervention
acid -X- _ I-Intervention
and -X- _ O
262 -X- _ O
who -X- _ O
did -X- _ O
not -X- _ O
receive -X- _ O
tranexamic -X- _ B-Intervention
acid -X- _ I-Intervention
were -X- _ O
compared. -X- _ O
We -X- _ O
also -X- _ O
analyzed -X- _ O
the -X- _ O
risk -X- _ O
factors -X- _ O
of -X- _ O
45 -X- _ O
and -X- _ O
284 -X- _ O
patients -X- _ O
who -X- _ O
did -X- _ O
and -X- _ O
did -X- _ O
not -X- _ O
experience -X- _ O
hematoma -X- _ B-Outcome
expansion -X- _ I-Outcome
, -X- _ O
respectively. -X- _ O
RESULTS -X- _ O
: -X- _ O
Hematoma -X- _ B-Outcome
expansion -X- _ I-Outcome
was -X- _ O
observed -X- _ O
in -X- _ O
7 -X- _ O
( -X- _ O
10.4 -X- _ O
% -X- _ O
) -X- _ O
of -X- _ O
67 -X- _ O
patients -X- _ O
in -X- _ O
the -X- _ O
tranexamic -X- _ B-Intervention
acid -X- _ I-Intervention
group -X- _ O
and -X- _ O
38 -X- _ O
( -X- _ O
14.5 -X- _ O
% -X- _ O
) -X- _ O
of -X- _ O
the -X- _ O
262 -X- _ O
patients -X- _ O
who -X- _ O
did -X- _ O
not -X- _ O
receive -X- _ O
tranexamic -X- _ B-Intervention
acid. -X- _ I-Intervention
There -X- _ O
was -X- _ O
no -X- _ O
statistically -X- _ O
significant -X- _ O
difference -X- _ O
between -X- _ O
patients -X- _ O
who -X- _ O
did -X- _ O
and -X- _ O
did -X- _ O
not -X- _ O
received -X- _ O
tranexamic -X- _ B-Intervention
acid -X- _ I-Intervention
( -X- _ O
p=0.389 -X- _ O
) -X- _ O
. -X- _ O
In -X- _ O
the -X- _ O
multivariate -X- _ O
logistic -X- _ O
regression -X- _ O
analysis -X- _ O
of -X- _ O
risk -X- _ O
factors -X- _ O
for -X- _ O
hematoma -X- _ B-Outcome
expansion -X- _ I-Outcome
, -X- _ O
spot -X- _ O
sign -X- _ O
and -X- _ O
a -X- _ O
maximal -X- _ O
diameter -X- _ O
of -X- _ O
40 -X- _ O
mm -X- _ O
were -X- _ O
identified -X- _ O
as -X- _ O
risk -X- _ O
factors. -X- _ O
CONCLUSION -X- _ O
: -X- _ O
We -X- _ O
could -X- _ O
not -X- _ O
confirm -X- _ O
the -X- _ O
effect -X- _ O
of -X- _ O
tranexamic -X- _ B-Intervention
acid -X- _ I-Intervention
on -X- _ O
hematoma -X- _ B-Patient
expansion -X- _ I-Patient
in -X- _ I-Patient
ICH -X- _ I-Patient
patients. -X- _ I-Patient
Spot -X- _ O
sign -X- _ O
and -X- _ O
the -X- _ O
maximal -X- _ O
diameter -X- _ O
of -X- _ O
hematomas -X- _ O
were -X- _ O
confirmed -X- _ O
as -X- _ O
risk -X- _ O
factors -X- _ O
of -X- _ O
hematoma -X- _ B-Outcome
expansion. -X- _ I-Outcome
If -X- _ O
the -X- _ O
maximal -X- _ O
diameter -X- _ O
is -X- _ O
greater -X- _ O
than -X- _ O
40 -X- _ O
mm -X- _ O
, -X- _ O
the -X- _ O
hematoma -X- _ O
should -X- _ O
be -X- _ O
closely -X- _ O
monitored -X- _ O
. -X- _ O

